CLINICAL ACTIVITY AND PHARMACOKINETICS (PK) OF CABOZANTINIB (XL184) IN PATIENTS WITH PROGRESSIVE MEDULLARY THYROID CARCINOMA (MTC)

被引：0
|
作者：
Cohen, E. E. W. [1 ]
Elisei, R. [2 ]
Schlumberger, M. J. [3 ]
Mueller, S. P. [4 ]
Schoeffski, P. [5 ]
Brose, M. [6 ]
Shah, M. [7 ]
Miles, D. R. [8 ]
Nguyen, L. T. [8 ]
Sherman, S. [9 ]
机构：
[1] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[2] Univ Pisa, Dept Endocrinol, Pisa, Italy
[3] Inst Canc Res, Villejuif, France
[4] Univ Klinikum Essen, Klin & Poliklin Nukl Med, Essen, Germany
[5] Univ Hosp Leuven, Dept Gen Med Oncol, Louvain, Belgium
[6] Univ Penn Hlth Syst, Dept Med, Philadelphia, PA USA
[7] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[8] Exelixis Inc, Nonclin Dev, San Francisco, CA USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disord, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：154 / 155
页数：2
相关论文
共 50 条
  • [21] Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).
    Buckanovich, R. J.
    Berger, R.
    Sella, A.
    Sikic, B. I.
    Shen, X.
    Ramies, D. A.
    Smith, D. C.
    Vergote, I. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with dear cell renal cell carcinoma (METEOR)
    Choueiri, Toni K.
    Escudier, Bernard J.
    Les, Thomas Pow
    Cella, David
    Ru, Qinhua C.
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
    Yang, Pei-Wen
    Liu, Yu-Cheng
    Chang, Ya-Han
    Lin, Ching-Ching
    Huang, Pei-Ming
    Hua, Kuo-Tai
    Lee, Jang-Ming
    Hsieh, Min-Shu
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [24] A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
    Choueiri, T. K.
    Escudier, B.
    Powles, T.
    Cella, D.
    Lee, Y.
    Laird, D. A.
    Scheffold, C.
    Motzer, R. J.
    BJU INTERNATIONAL, 2013, 112 : 4 - 4
  • [25] Anti-tumor activity observed in an ongoing phase 1 drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma
    Choueiri, T. K.
    Pal, S. K.
    McDermott, D. M.
    Ramies, D. A.
    Morrissey, S.
    Lee, Y.
    Miles, D.
    Holland, J. S.
    Dutcher, J. P.
    BJU INTERNATIONAL, 2012, 109 : 4 - 4
  • [26] Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)
    Winer, Eric P.
    Tolaney, Sara
    Nechushtan, Hovav
    Berger, Raanan
    Kurzrock, Razelle
    Ron, Ilan-Gil
    Schoffski, Patrick
    Awada, Ahmad
    Yasenchak, Christopher A.
    Burris, Howard A.
    Ramies, David A.
    Rafferty, Teresa
    Shen, Xiaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Heather A. Wakelee
    Scott Gettinger
    Jeffrey Engelman
    Pasi A. Jänne
    Howard West
    Deepa S. Subramaniam
    Joseph Leach
    Michael Wax
    Yifah Yaron
    Dale R. Miles
    Primo N. Lara
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 923 - 932
  • [28] A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC)
    Kurzrock, R.
    Sherman, S.
    Hong, D.
    Ng, C.
    Frye, J.
    Janisch, L.
    Ratain, M. J.
    Salgia, R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 119 - 119
  • [29] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Wakelee, Heather A.
    Gettinger, Scott
    Engelman, Jeffrey
    Janne, Pasi A.
    West, Howard
    Subramaniam, Deepa S.
    Leach, Joseph
    Wax, Michael
    Yaron, Yifah
    Miles, Dale R.
    Lara, Primo N., Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 923 - 932
  • [30] Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET
    Kurzrock, R.
    Cohen, E. E.
    Sherman, S. I.
    Pfister, D. G.
    Cohen, R. B.
    Ball, D.
    Hong, D. S.
    Ng, C. S.
    Salgia, R.
    Ratain, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345